证券代码：600645 证券简称：中源协和 公告编号：2023-029 中源协和细胞基因工程股份有限公司 十一届二次董事会会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 中源协和细胞基因工程股份有限公司（以下简称"公司"）十一届二次董事 会会议于 2023 年 8 月 24 日以通讯表决方式召开。会议通知和会议资料已于 2023 年 8 月 14 日以电子邮件形式向全体董事发出。应出席会议的董事 9 名，实际出 席会议的董事 9 名。会议符合《公司法》和《公司章程》的规定，表决有效。经 出席会议的董事认真审议，通过了以下决议： 1、以 9 票赞成、0 票反对、0 票弃权，审议通过了《公司 2023 年半年度报 告》全文及摘要； 1 2019-029）。截至目前，公司仍通过源聚福持有泛生子 15,035,000 股普通股。 日前接泛生子通知，泛生子拟进行私有化并从纳斯达克交易所退市。根据私 有化交易方案，泛生子与为本次私有化交易出资设立的特殊目的公司：New Genetron Holding Limited（以下简 ...

证券代码：600645 证券简称：中源协和 公告编号：2023-031 中源协和细胞基因工程股份有限公司 2023 年半年度募集资金存放与实际使用情况的专项 报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、募集资金基本情况 1、实际募集资金金额及到账时间 根据中国证券监督管理委员会《关于核准中源协和细胞基因工程股份有限公 司向王晓鸽等发行股份购买资产并募集配套资金的批复》（证监许可[2018]1180 号）核准文件，公司实际非公开发行人民币普通股27,815,801股，发行价格为 16.07元，募集资金总额为446,999,922.07元，扣除相关发行费用（包括承销及 保荐费用、验资费用、律师费用等）2,550,000元，公司实际募集资金净额 444,449,922.07元。本次募集资金已于2019年7月22日全部到账，瑞华会计师事 务所（特殊普通合伙）就公司新增注册资本的实收情况出具了《验资报告》（瑞 华验字[2019]12010004号）。 2、募集资金使用金额及当前余额 公司募集资金使用情况如下： | 项目 | ...

证券代码：600645 证券简称：中源协和 公告编号：2023-028 申请人：武汉光谷中源药业有限公司 审批结论：根据美国《联邦食品、药品和化妆品法案》第 526 条，授予武汉 光谷中源药业人脐带源间充质干细胞用于特发性肺纤维化适应症的孤儿药资格。 中源协和细胞基因工程股份有限公司 关于全资子公司产品获得美国 FDA 孤儿药资格认定 的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 2023 年 4 月 7 日，公司披露《关于全资子公司获得药物临床试验批准通知 书的公告》，全资子公司武汉光谷中源药业有限公司（以下简称"武汉光谷中源 药业"）VUM02 注射液用于治疗特发性肺纤维化获得国家药品监督管理局批准， 进入临床试验。具体内容详见公司公告：2023-008。 近日，武汉光谷中源药业产品 VUM02 注射液用于治疗特发性肺纤维化（IPF） 获得美国食品药品监督管理局（以下简称"美国 FDA"）授予的孤儿药资格认定。 现将相关情况公告如下： 一、基本情况 药品名称：VUM02 注射液（人脐带源间充质干细胞注射液） 适应 ...

中源协和细胞基因工程股份有限公司 关于召开 2022 年度业绩说明会的公告 证券代码：600645 证券简称：中源协和 公告编号：2023-018 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ●召开时间：2023年5月19日（星期五）15:00-16:30 ●召开地点：中国证券报中证网 （https://www.cs.com.cn/roadshow/yjsmh/） ●召开方式：网络视频播放和网络文字互动 ● 投资者 可 在 2023 年 5 月 18 日 17:00 前 通过公司邮箱 zhongyuanxiehe@vcanbio.com进行提问，公司将在业绩说明会上对投资者普遍关 注的问题进行回答。或在召开当天15:00-16:30登录中国证券报中证网参与本次 互动交流。 一、说明会类型 中源协和细胞基因工程股份有限公司（以下简称"公司"）于2023年4月26 日发布了2022年年度报告。为便于广大投资者更深入全面地了解公司情况，公司 将在中国证券报中证网以网络方式举行2022年度业绩说明会。 二、召开时间 ...

Financial Performance - The company's audited net profit for 2022 was -56.21 million RMB, resulting in a cumulative undistributed profit of -213 million RMB as of December 31, 2022, leading to no profit distribution to shareholders [5]. - Operating revenue for 2022 was 1,554.89 million RMB, a 1.27% increase from 2021 [19]. - Net profit attributable to shareholders decreased by 27.26% year-on-year, primarily due to the previous year's fair value increase of Aceso's fund holdings [21]. - The cash flow from operating activities for 2022 was 261.89 million RMB, down 18.40% from 2021 [19]. - The basic earnings per share for 2022 was 0.24 RMB, a decrease of 27.27% from 2021 [21]. - The weighted average return on net assets for 2022 was 3.23%, down 1.29 percentage points from the previous year [21]. - The company reported a net asset value attributable to shareholders of 3,555.80 million RMB at the end of 2022, an increase of 2.67% from the end of 2021 [19]. - The company reported non-recurring gains and losses totaling 8.95 million yuan for 2022, a significant decrease from 100.27 million yuan in 2021 [25]. - The net profit attributable to shareholders for Q3 was 49.72 million yuan, while Q4 reported a loss of 1.56 million yuan [24]. - The company reported a significant decrease in financial expenses by 77.23%, attributed to increased interest income from deposits [81]. Research and Development - R&D investment totaled CNY 158.68 million in 2022, representing 10.21% of operating revenue, with R&D personnel increasing to 248, accounting for 10.63% of total staff [44]. - The company is actively conducting 74 research projects related to stem cell research and product development, with 38 projects completed [96]. - The company has developed a diverse product range, including over 27,000 human-derived proteins and 140,000 primary antibodies, positioning itself as a leading provider in the research field [72]. - The company aims to enhance its competitive edge by expanding its clinical cooperation and product lines, focusing on precision medicine [126]. - The company plans to push forward with stem cell drug applications and clinical trials, with IND acceptance for multiple indications [127]. Market Trends and Opportunities - The Chinese cell therapy market is projected to grow from 1.3 billion RMB in 2021 to 58.4 billion RMB by 2030, with an annual growth rate of 53% [116]. - The CAR-T therapy market in China is expected to expand from 200-300 million RMB in 2021 to 28.7 billion RMB by 2030 [116]. - The in vitro diagnostics market in China is expected to grow rapidly, with the company focusing on product quality and innovation to maintain a competitive advantage [138]. - The global life science reagent market reached $17.5 billion in 2019 and is expected to grow to $24.6 billion by 2024, with the Chinese market projected to reach ¥26 billion by 2024 [63]. Strategic Initiatives - The company is actively pursuing market expansion and new product development in the precision medicine sector, enhancing its upstream and downstream synergy effects [113]. - The company is exploring potential mergers and acquisitions to enhance its product portfolio and market reach, with a budget of 200 million set aside for this purpose [154]. - The company signed a strategic cooperation framework agreement with the Tianjin Cell Ecology Haihe Laboratory to enhance innovation and industrialization of cell-derived products [76]. - The company is collaborating with key hospitals to establish a research and development transformation platform, with multiple clinical studies currently underway [42]. Governance and Compliance - The company adheres to strict governance practices, ensuring compliance with laws and protecting shareholder rights [141]. - The board of directors consists of 9 members, including 3 independent directors, ensuring proper governance and oversight [143]. - The company has established a comprehensive performance evaluation standard and procedure for senior management to promote sustainable development [144]. - The company has implemented measures to ensure compliance with insider information management regulations [145]. Environmental Responsibility - Wuxi Aorui Company discharged 13,284.96 tons of domestic sewage and 1,229.28 tons of industrial wastewater in 2022, with COD emissions of 2.655 tons and 0.117 tons respectively [184]. - Both companies' wastewater and air emissions were reported to be below national standards during the reporting period [185][187]. - The companies are committed to complying with environmental protection laws and ensuring proper waste treatment and emissions standards [195]. Challenges and Risks - The company is facing industry policy risks due to potential future regulations in the fields of stem cells and gene testing, which may impact operations [133]. - Talent retention is a concern as the company expands, with strategies in place to align management and core talent interests to mitigate risks of talent loss [134]. - The newborn storage business is dependent on birth rates, which are declining, prompting the company to enhance service quality and expand into adult cell storage [137].

Financial Performance - Total operating revenue for Q1 2023 was ¥377,745,248.80, a decrease of 4.4% compared to ¥394,174,107.03 in Q1 2022[22]. - Total operating costs for Q1 2023 were ¥323,064,529.03, down 3.5% from ¥335,382,040.09 in Q1 2022[22]. - Net profit for Q1 2023 was ¥35,256,628.40, a slight decrease of 2.7% from ¥36,246,721.16 in Q1 2022[23]. - The net profit attributable to shareholders for Q1 2023 was CNY 37,373,824.55, an increase of 4.33% year-over-year[30]. - The total comprehensive income for Q1 2023 was ¥23,039,552.43, compared to a loss of ¥42,196,397.05 in Q1 2022[23]. - Basic earnings per share remained stable at ¥0.08 for both Q1 2023 and Q1 2022[23]. - The company reported a basic earnings per share of CNY 0.08 for Q1 2023, unchanged from the previous year[30]. Assets and Liabilities - The total assets as of Q1 2023 were 5,247,791,551.14 RMB, a decrease from 5,284,619,414.55 RMB in the previous period[19]. - The total non-current assets were 2,950,834,014.00 RMB, down from 2,974,590,727.49 RMB[19]. - The total current liabilities decreased to 1,412,669,461.64 RMB from 1,471,494,581.46 RMB[19]. - The total liabilities amounted to ¥1,571,850,968.19, a decrease from ¥1,630,964,993.11 in the previous period[20]. - The equity attributable to shareholders of the parent company was ¥3,577,205,736.94, an increase from ¥3,555,802,379.28[20]. - The equity attributable to shareholders increased to CNY 3,577,205,736.94, reflecting a growth of 0.60% year-over-year[31]. Cash Flow - The net cash flow from operating activities for Q1 2023 was CNY 27,030,268.28, down by 10.09% compared to Q1 2022[30]. - Cash received from operating activities totaled CNY 402,970,860.77 in Q1 2023, slightly up from CNY 402,509,153.30 in Q1 2022[25]. - Cash paid for goods and services in Q1 2023 was CNY 102,356,677.01, down from CNY 106,814,353.67 in the same period last year[25]. - Investment activities generated a net cash flow of -$22.64 million, compared to -$24.44 million in the previous period, indicating an improvement of approximately 7.3%[46]. - Cash outflow from investment activities totaled $32.65 million, up from $24.52 million year-over-year, representing a 33.1% increase[46]. - Cash flow from financing activities resulted in a net outflow of -$9.74 million, compared to -$8.74 million in the previous period, reflecting an 11.4% increase in outflow[46]. - The ending balance of cash and cash equivalents was $1.37 billion, slightly down from $1.19 billion in the previous year[46]. Research and Development - R&D expenses increased to ¥33,453,290.77 in Q1 2023, up 15.5% from ¥29,027,540.94 in Q1 2022[22]. - Clinical trial applications for the VUM02 injection have been accepted, with approvals for two indications received in February and April 2023[15]. Other Income and Expenses - Government subsidies recognized in the current period amounted to 1,075,325.83 RMB[5]. - The impairment provision reversal for receivables and contract assets was 139,815.00 RMB[5]. - Other operating income and expenses, excluding the above items, totaled 257,734.20 RMB[5]. - The total non-recurring profit and loss items amounted to 941,882.66 RMB after tax and minority interest adjustments[5]. - The company reported a decrease in other comprehensive income after tax of ¥12,217,075.97 compared to a loss of ¥78,443,118.21 in the previous year[23].

Financial Performance - The company's operating revenue for Q3 2022 was ¥407,415,406.55, representing a year-on-year increase of 4.01%[6] - The net profit attributable to shareholders for Q3 2022 was ¥49,718,296.95, a decrease of 37.94% compared to the same period last year[6] - The net profit attributable to shareholders after deducting non-recurring gains and losses increased by 111.58% year-on-year, indicating strong growth in reagent business revenue[13] - The basic earnings per share for Q3 2022 was ¥0.10, down 41.18% from the previous year[9] - Net profit for the third quarter of 2022 was ¥113,460,668.07, down from ¥194,586,517.04 in the same quarter of 2021, reflecting a decrease of approximately 41.7%[33] - The company reported a total comprehensive income of ¥81,470,494.05 for the third quarter of 2022, compared to ¥186,621,508.15 in the same quarter of 2021, a decrease of about 56.4%[35] - The company experienced a decrease in investment income, reporting ¥2,188,625.17 in 2022 compared to ¥20,486,959.81 in 2021, a decline of about 89.3%[30] Assets and Liabilities - The total assets at the end of the reporting period were ¥5,226,937,505.02, an increase of 3.85% compared to the end of the previous year[9] - As of September 30, 2022, the company's total assets amounted to RMB 5,226,937,505.02, an increase from RMB 5,033,377,672.10 as of December 31, 2021, representing a growth of approximately 3.84%[22] - The total liabilities of the company were RMB 1,596,406,723.50, compared to RMB 1,500,617,384.63 at the end of 2021, reflecting a rise of approximately 6.38%[28] - The total owner's equity was RMB 3,630,530,781.52, reflecting a stable position compared to the previous year[28] - The company’s total liabilities and equity increased to ¥5,226,937,505.02 in 2022 from ¥5,033,377,672.10 in 2021, reflecting a growth of approximately 3.8%[30] Cash Flow - The net cash flow from operating activities for the year-to-date was ¥178,308,231.45, reflecting a decrease of 23.34%[9] - The net cash flow from operating activities was 178,308,231.45, a decrease of 23.3% compared to 232,588,634.00 from the previous period[40] - Total cash inflow from financing activities was 17,500,000.00, significantly higher than 692,100.00 in the previous period[42] - The net cash flow from investing activities was -71,251,901.56, an improvement from -92,456,340.77 in the previous period[40] - Cash and cash equivalents at the end of the period reached 1,317,810,007.20, up from 1,176,968,867.46 in the previous period[42] - The total cash outflow from financing activities was 39,740,742.26, compared to 22,629,667.81 in the previous period, indicating increased financial obligations[42] - The cash inflow from operating activities totaled 1,235,684,087.35, slightly down from 1,245,397,088.82 in the previous period[40] - The cash outflow for purchasing goods and services was 299,916,803.09, an increase from 283,025,699.27 in the previous period[40] - The company received tax refunds amounting to 4,749,499.19, compared to 1,193,803.99 in the previous period, showing improved tax recovery[40] - The cash inflow from investment activities was 3,025,864.67, a significant decrease from 71,836,563.12 in the previous period[40] - The net increase in cash and cash equivalents for the period was 127,737,045.60, compared to 116,649,488.84 in the previous period[42] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 38,183[14] - The largest shareholder, Tianjin Deyuan Health Management Co., Ltd., held 12.14% of the shares, with a significant portion pledged[16] Research and Development - Research and development expenses for the first three quarters of 2022 were ¥109,497,085.50, up from ¥102,165,541.66 in 2021, marking an increase of about 7.3%[30]

Financial Performance - The company's operating revenue for the first half of 2022 was approximately RMB 768.80 million, a slight increase of 0.09% compared to RMB 768.10 million in the same period last year[21]. - The net profit attributable to shareholders of the listed company decreased by 41.44% to RMB 64.83 million from RMB 110.70 million year-on-year[21]. - The net profit after deducting non-recurring gains and losses was RMB 54.22 million, down 25.17% from RMB 72.45 million in the previous year[21]. - The net cash flow from operating activities was RMB 105.78 million, a decrease of 13.60% compared to RMB 122.43 million in the same period last year[21]. - Basic earnings per share decreased by 41.67% to RMB 0.14 from RMB 0.24 in the same period last year[22]. - The weighted average return on net assets was 1.87%, down 1.29 percentage points from 3.16% in the previous year[25]. - The company achieved operating revenue of 769 million RMB, a year-on-year increase of 0.09%[26]. - The decline in net profit was primarily due to the previous year's full exemption of the "U.S. PPP loan" and a decrease in the fair value changes of investments in associated companies[26]. - The company reported a gross margin of 74.82% in the service sector, which decreased by 2.62% compared to the previous year[53]. - In the manufacturing sector, the gross margin was 65.92%, reflecting a decrease of 0.95% year-on-year[53]. Assets and Liabilities - The total assets at the end of the reporting period were RMB 5.11 billion, an increase of 1.53% from RMB 5.03 billion at the end of the previous year[21]. - The net assets attributable to shareholders of the listed company increased by 0.41% to RMB 3.48 billion from RMB 3.46 billion at the end of the previous year[21]. - Total assets increased to CNY 5,110,355,629.70, up from CNY 5,033,377,672.10, representing a growth of 1.53%[178]. - Current liabilities rose to CNY 1,415,375,843.32, compared to CNY 1,395,646,643.11, reflecting an increase of 1.27%[178]. - Total liabilities amounted to CNY 1,547,942,962.15, up from CNY 1,500,617,384.63, indicating a growth of 3.15%[178]. - Shareholders' equity increased to CNY 3,562,412,667.55 from CNY 3,532,760,287.47, marking a rise of 0.84%[178]. Research and Development - The company is actively advancing clinical projects and cell drug development to improve its research and development capabilities[30]. - R&D expenses decreased by 7.69% to 64.51 million RMB compared to the previous year[62]. - The company has established a GMP-grade iPSC library to accelerate the process of allogeneic cell therapy[49]. - The company plans to focus on market expansion and new product development as part of its future strategy[184]. - The company is focused on developing new products in the in vitro diagnostic sector to maintain market competitiveness[88]. Market and Industry Trends - The company operates in the "precision medicine" sector, focusing on cell detection, in vitro diagnostics, and stem cell applications[30]. - The domestic in vitro diagnostic market is expected to maintain rapid growth due to factors such as economic development, healthcare reform, aging population, and increased disposable income, with significant market potential ahead[91]. - The government is prioritizing the development of immune cell therapy and gene therapy, indicating a strong future market for these technologies[33]. - The emphasis on early disease prevention and health services aligns with the growing consumer demand for healthcare solutions[33]. Corporate Governance and Compliance - The company has established independent financial and operational structures to maintain the integrity of its assets and financial decisions[114]. - The company has committed to not engaging in competitive business activities with the listed company and will ensure compliance with relevant regulations regarding related party transactions[111]. - The company guarantees the independence of its financial personnel, ensuring they do not hold positions or receive compensation from related enterprises[126]. - The company has established a robust organizational structure to ensure independent governance and decision-making processes[120]. Legal and Regulatory Matters - The company has ongoing significant litigation regarding a land use rights transfer dispute, with a judgment requiring a repayment of 71.21 million yuan from Singapore Huide Investment Holdings Co., Ltd.[145]. - The company is involved in a lawsuit concerning a 67% equity transfer dispute, with a settlement requiring a payment of 30 million yuan, of which only 1 million yuan has been received to date, leaving a balance of 29 million yuan outstanding[145]. - There are no significant guarantees or violations reported during the reporting period[142]. - The company has not faced any standard audit opinion issues in the previous annual report[145]. Social Responsibility - The company has been recognized for its social responsibility efforts, including the establishment of the "Zhongyuan Harmony Life Science Award" to support young scientists[44].

证券代码：600645 证券简称：中源协和 公告编号：2022-047 中源协和细胞基因工程股份有限公司 关于参加 2022 年度天津辖区上市公司半年报业绩说 明会与投资者网上集体接待日活动公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ●召开时间：2022年9月6日（星期二）13:40-16:40 ●召开地点：全景路演（http://rs.p5w.net） ●召开方式：网络方式召开 一、会议情况 为进一步加强与投资者的沟通交流，公司定于2022年9月6日（星期二） 13:40-16:40在全景路演参加2022年度天津辖区上市公司半年报业绩说明会与投 资者网上集体接待日活动。本次活动将采用网络远程的方式举行，投资者可登录 全景路演（http://rs.p5w.net）参与本次互动交流，与公司互动交流时间为 15:00-16:30。 二、召开时间和方式 时间：2022年9月6日（星期二）13:40-16:40 地点：全景路演（http://rs.p5w.net） 方式：网络方式召开 三、公司出席人员 公司出 ...

Financial Performance - The company's operating revenue for Q1 2022 was RMB 394,174,107.03, representing a year-on-year increase of 7.50%[6] - The net profit attributable to shareholders of the listed company was RMB 35,823,760.85, showing a decrease of 21.36% compared to the same period last year[6] - The basic and diluted earnings per share were both RMB 0.08, reflecting a decline of 20.00% year-on-year[6] - Net profit for Q1 2022 was approximately RMB 36.25 million, a decrease of 20.9% from RMB 45.81 million in Q1 2021[34] - The total equity attributable to shareholders decreased to approximately RMB 3.42 billion in Q1 2022 from RMB 3.46 billion in Q1 2021, a decline of 1.2%[32] - The total comprehensive income attributable to the parent company was -42,619,357.36 CNY, compared to 198,663,061.28 CNY in the previous year, indicating a significant decline[37] Cash Flow and Liquidity - The net cash flow from operating activities decreased by 38.83% to RMB 30,064,712.75, primarily due to increased procurement costs and higher performance bonuses paid to employees[11] - The net cash flow from operating activities was 30,064,712.75 CNY, down from 49,151,166.35 CNY year-over-year, reflecting a decrease of approximately 38.9%[41] - Cash received from the sale of goods and services was 395,390,920.90 CNY, an increase of 4.1% from 380,293,037.07 CNY in the previous year[41] - The total cash outflow from operating activities was 372,444,440.55 CNY, compared to 337,776,132.89 CNY in the previous year, reflecting an increase of approximately 10.2%[41] - The cash outflow from financing activities was 8,739,581.93 CNY, compared to 2,489,757.56 CNY in the previous year, indicating a significant increase in cash outflow[43] - The net cash flow from investment activities was -24,442,765.20 CNY, an improvement from -69,072,037.84 CNY in the previous year, showing a reduction in cash outflow from investments[41] Assets and Liabilities - Total assets at the end of the reporting period were RMB 5,042,570,476.68, a slight increase of 0.18% from the end of the previous year[9] - The company's total liabilities increased to approximately RMB 1.55 billion in Q1 2022 from RMB 1.50 billion in Q1 2021, reflecting a growth of 3.7%[30] - As of March 31, 2022, the total current assets amounted to RMB 2,083,470,848.81, an increase from RMB 2,030,210,899.72 at the end of 2021[27] - The company's non-current assets totaled RMB 2,959,099,627.87, down from RMB 3,003,166,772.38 at the end of 2021[27] - The company's accounts receivable increased to RMB 498,494,250.32 from RMB 456,387,269.65 at the end of 2021, reflecting a growth of approximately 9.1%[27] - The company reported a decrease in cash and cash equivalents to RMB 1,190,853,808.99 from RMB 1,195,655,271.02 at the end of 2021[27] Shareholder Information - The total number of common shareholders at the end of the reporting period was 38,735[14] - The largest shareholder, Tianjin Development Zone Deyuan Investment Development Co., Ltd., held 12.14% of the shares, amounting to 56,787,503 shares[14] Investments and Agreements - The company invested RMB 20 million in Shanghai Zhongyuan Jisheng Cell Technology Co., holding a 50% equity stake after the capital increase[19] - The company signed a real estate lease agreement with Shanghai Yanlan Biotechnology Co., with an annual rent of RMB 7,256,784 for a 5,232 square meter property[22] - The total rental payment after discounts is RMB 60,956,985.60, with the first payment of RMB 17,960,540.40 due initially[22] Research and Development - Research and development expenses for Q1 2022 were approximately RMB 29.03 million, slightly down from RMB 29.77 million in Q1 2021[32] Other Financial Metrics - Non-recurring gains and losses totaled RMB 379,000.08 for the period, with government subsidies contributing RMB 273,114.23[10] - The weighted average return on net assets was 1.04%, a decrease of 0.26 percentage points compared to the previous year[6] - The company's deferred income tax liabilities were approximately RMB 34.12 million in Q1 2022, slightly down from RMB 34.70 million in Q1 2021[30] - The total comprehensive income for Q1 2022 included a significant other comprehensive loss of approximately RMB 78.44 million, contrasting with a gain of RMB 153.11 million in Q1 2021[34] - The company's cash and cash equivalents were not explicitly stated but are implied to be part of the overall financial health reflected in the total assets of approximately RMB 5.04 billion[32] - The company reported a credit impairment loss of approximately RMB 5.32 million in Q1 2022, compared to RMB 6.07 million in Q1 2021, indicating an improvement[34]